UnitedHealth Group reported strong Q2 results with beats on revenue and EPS, and raised its full-year 2026 guidance. The company maintained a stable medical loss ratio of 86.7%, and analysts have upgraded EPS estimates with no downgrades, reflecting confidence in its long-term growth. Despite recent underperformance against the S&P 500, UnitedHealth's valuation remains attractive with a 6.9% free cash flow yield. Technically, the stock shows a bullish primary trend but faces key support levels around mid-$350s, with potential downside if it drops below $370.
Following UnitedHealth's upbeat 2026 outlook, its stock price on Pluang stands at USD 382.00 as of Sep 15, 2026 16:41 WIB, showing a slight 0.40% decline over the day. The company holds a market capitalization of $340.27 billion and offers a dividend yield of 2.45%, reflecting its strong position in the health sector despite recent price fluctuations.
The Schwab US Dividend Equity ETF (SCHD) has delivered strong price returns of 33% over the past year, yet its dividend income has grown only modestly by about 2%. The fund's top holdings, including Qualcomm, Texas Instruments, UnitedHealth, and Coca...
UnitedHealth Group is focused on expanding its operating margins rather than growing revenue, with margins expected to rebound to 7.8–8.0% by 2030. This improvement is driven by repricing strategies, Medicaid rate adjustments, and restructuring withi...
The Schwab U.S. Dividend Equity ETF (SCHD) has grown to nearly $95 billion in assets, attracting retirees with a 3.2% dividend yield from a portfolio of financially strong companies. Its top holdings include Qualcomm, UnitedHealth, Coca-Cola, and Tex...
UnitedHealth Group is initiated with a Strong Buy rating and a $533 price target, suggesting 33% upside from its current price. The positive outlook is driven by margin recovery, Optum Health's move to higher-quality contracts, and AI-enhanced effici...
UnitedHealth Group was downgraded from strong buy to buy because its shares appear fully valued at a 20x forward price-to-earnings ratio. The company reported better-than-expected Q3 earnings with revenue of $112.7 billion and earnings per share of $...
